久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Aptabio to initiate Phase II oral Covid-19 therapy trial pharmaceutical-technology
    March 29, 2021
    South Korean company Aptabio is all set to initiate a Phase II trial of its oral therapy, APX-115, for treating Covid-19.A transmembrane enzyme NADPH oxidase (NOX) inhibitor, APX-115 was studied in Europe for treating patients with diabetes complications.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service